THROMBOSIS RESEARCH Pergamon Thrombosis Research 88 (1997) 509-520 Author Index—Volumes 81-84 (1996) Aasen, A.O., see Karlsrud, T.S. 82:265 Ataullakhanov, F.I., see Zarnitsina, V.I. 84:225, 333 Abbate, R., see Boddi, M. 82:207 Atkinson, A., see Bessos, H. 84:367 , see Chiarantini, E. 82:137 , see Huggan, P.J. 81:339 ———., see Comeglio, P. 84:199 Austin, H., see Hooper, W.C. 81:577 ———., see Gensini, G.F. 84:1 Avellone, G., V. Di Garbo, R. Cordova, G. Abruzzese, G. Rotolo, , see Martini, F. 83:299 R. De Simone, G. Raneli, G. Bompiani. Activation of coagula- Abe, S., see Goto, S. 84:351 tion but normal fibrinolysis in patients with type II, hyperlipo- Abella, A., see Keddad, K. 82:159 proteinemia. 81:277 Abildgaard, U., see Andersson, T. 82:109 Aznar, J., see Jorquera, J.1. 82:217 , see Iversen, N. 84:267 , see Martinez, M. 83:375 Abruzzese, G., see Avellone, G. 81:277 Azougagh Oualane, F., see Belougne, E. 82:453 Aguejouf, O., see Belougne, E. 82:453, 84:189, 207 , see Doutremepuich, C. 83:217 , see Imbault, P. 82:469 Azzadin, A., see Mysliwiec, J. 83:175 Ahlburg, P., see Knudsen, L. 84:45 Ajenjo, C., see Aranda, E. 84:67 Akay, H., see Ozdemir, O. 84:121 Baba, S., see Rydzewski, A. 84:445 Bach-Gansmo, E.T., S. Halvorsen, H.C. Godal, O.H. Skjgnsberg. Akin, R., see Tanindi, §. 81:471 D-dimers are degraded by human neutrophil elastase. 82:177 Albanese, A., see Magnani, A. 81:383 Badimon, J.J., see Pueyo, C. 81:101 Alessandri, C., see Basili, S. 84:279 Badimon, L., see Pueyo, C. 81:101 Aljada, A., see Dandona, P. 81:163 Baglin, T.P., see Rota, S. 83:329 Amirkhosravi, A., J.P. Biggerstaff, G. Warnes, D.A. Francis, J.L. Baillie, J., see Bessos, H. 84:367 Francis. Determination of tumor cell procoagulant activity by Baj, Z., see Golanski, J. 83:199 Sonoclot™ analysis in whole blood. 84:323 Bal dit Sollier, C., L. Drouet, G. Pignaud, C. Chevallier, J. Caen, Andersen, B.S., see Rahr, H.B. 81:607 A.-M. Fiat, C. Izquierdo, P. Jollés. Effect of x-casein split pep- Anderson, S.M., see Maciejewski, J.P. 83:433 tides on platelet aggregation and on thrombus formation in the Andersson, T., B. Lorentzen, H. H@gdahl, T. Clausen, M.-C. Mo- guinea-pig. 81:427 winckel, U. Abildgaard. Thrombin-inhibitor complexes in the Bal dit Sollier, C., see André, P. 83:127 blood during and after delivery. 82:109 Balestrieri, A., see Marongiu, F. 84:379 André, P., P. Hainaud, C. Bal dit Sollier, V. Drouet, L.1. Garfinkel, Balle Petersen, L., see Stephens, R.W. 84:453 A. Uzan, J.P. Caen, L.O. Drouet. Guinea pig blood: a model for the pharmacologic modulation of the GPIb/IX-VWFE axis. Bangalore, N., see Lee, T.K. 82:225 $3:127 Bara, L., see Gerotziafas, G.T. 81:491 André, P., see Roussi, J. 81:297 , see Tardy, B. 83:153 Anfossi, G., P. Massucco, L. Mattiello, V. Piretto, E. Mularoni, Barbanti, M., see Dettori, A.G. 83:103 F. Cavalot, G. Paoletti, M. Trovati. Insulin exerts opposite Barbucci, R., see Magnani, A. 81:383 effects on platelet function at physiological and supraphysiolog- Barcellona, D., G. Mameli, F. Marongiu. Inhibition of blood coag- ical concentrations. 82:57 ulation activation and oral anticoagulants in patients with me- Ankri, A., see Bastard, J.-P. 81:271 chanical heart valve prostheses. 81:403 Aoki, N., see Ikematsu, S. 82:129 Barcellona, D., see Marongiu, F. 84:379 Baris, I., see Ozdemir, O. 84:121 Aoki, T., D. Cox, K. Senzaki, J. Seki, A. Tanaka, H. Takasugi, Barista, I., see Demiroglu, H. 84:297 Y. Motoyama. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIla antagonist. 81:439 Bark, N., B. Blombiack, K. Fatah. On the occurrence of thrombin- Aranda, E., J. Pereira, C. Ajenjo, C. Prieto, S. Sepulveda, D. like enzymes in mosquitoes. 81:623 Mezzano. Human intraplatelet 5-hydroxytryptamine is corre- Barna, L., see Hoagland, L.E. 83:363 lated with mean platelet survival time. 84:67 , see Peng, F. 82:193, 83:243 Arcieri, P., see Coniglio, M. 83:183 Basili, S., P. Ferroni, F.M. Pulcinelli, G. Pettirossi, M. Vieri, F. Ardlie, N.G., see Selley, M.L. 83:449 Violi, C. Alessandri, C. Cordova, P.P. Gazzaniga. Potential Ariyoshi, H., see Kambayashi, J.-i. 81:85 usefulness of antiplatelet agents in patients with chronic ob- Asazuma, N., see Qi, R. 81:43 structive pulmonary disease. 84:279 , see Satoh, K. 81:515 Bastard, J.-P., E. Bruckert, D. Porquet, C. Jardel, A. Ankri, J. Aschka, I., see Nowak-Gottl, U. 81:665 Delattre, B. Hainque. Evidence for a relationship between plas- 0049-3848/97 $17.00 + .00 © 1998 Elsevier Science Ltd. Printed in the USA. All rights reserved. PII S0049-3848(98 )00057-7 510 Author Index/Thrombosis Research 88 (1997) 509-520 minogen activator inhibitor-1 and gamma glutamyl trans- Anti-thrombotic activity of RG13965, a novel platelet fibrino- ferase. $1:271 gen receptor antagonist. 82:495 Baussan, Ch., see Keddad, K. 82:159 Bottasso, B., D. Mari, R. Coppola, N. Santoro, M. Vaglini, P.M. Bayram, C., see Siier, S. 83:77 Mannucci. Hypercoagulability and hyperfibrinolysis in patients Bean, C., see Lacroix, K.A. 81:133 with melanoma. 81:345 Becher, H., see Grau, A.J. 82:245 Boutcher, P.A., P.J. Gaffney, S. Raut, R.G. O’Regan, P. McLough- Beck, E.A., see Steinmann, C. 81:145 lin. Effects of early plasmin digests of fibrinogen on isometric Beckmann, R., see Zehetgruber, M. 83:143 tension development in isolated rings of rat pulmonary ar- Bednar, J., see Sinzinger, H. 82:291 tery. $1:231 Bellaiche, L., see Knudsen, L. 84:45 Box, L., see Lacroix, K.A. 81:133 Belougne, E., O. Aguejouf, F. Doutremepuich, C. Doutreme- Brandt, J.T., see McAndrew, P.E. 83:195 puich. Action of neurotransmitters: acetylcholine, adrenaline Bregengaard, C., see Holst, J. 81:461 and serotonin on arterial thrombosis induced by a laser Brodniewicz, T., see Cierniewski, C.S. 82:349 beam. 84:189 Brosstad, F., see Bennick, A. 82:169 . Aspirin fails to prevent experimental arterial thrombosis Brown, N.L., see Millet, J. 81:497 induced by oxygen free radicals. 84:207 Bruckert, E., see Bastard, J.-P. 81:271 Belougne, E., O. Aguejouf, P. Imbault, F. Azougagh Oualane, F. Buczko, W., see Chabielska, E. 82:69 Doutremepuich, M.T. Droy-Lefaix, C. Doutremepuich. Experi- , see Malyszko, J. 83:351 mental thrombosis model induced by laser beam. Application ———., see Mysliwiec, J. 83:175 of aspirin and an extract of Ginkgo Biloba: EGb 761. 82:453 , see Pawlak, D. 83:189 Belougne, E., see Inamo, J. 83:229 Buggle, F., see Grau, A.J. 82:245 Bennick, A., U. Haddeland, F. Brosstad. D-dimer specific mono- Bug, L., see Karlsrud, T.S. 82:265 clonal antibodies react with fibrinogen aggregates. 82:169 Burke, S.E., D.J. Davidson, N.L. Lubbers, I.M. Reininger, J. Hen- kin. Differential effects of lys- and mini- plasminogen on clot Benson, J., see Hooper, W.C. 81:577 lysis induced by recombinant urokinase and recombinant pro- Benson, J.M., D.J. Phillips, B.P. Holloway, B.L. Evatt, W.C. urokinase in a canine thrombosis model. 83:421 Hooper. Oligonucleotide ligation assay for detection of the Bussel, J.A., see Pfaffenbach, G.M. 81:353 factor V mutation (Arg™’—Gln) causing protein C resistance. Byrne, C.D., see Rota, S. 83:329 83:87 Bergonzini, G.L., see Mascellani, G. 84:21 Bergqvist, D., see Henriksson, A.E. 82:409 Caen, J., see Bal dit Sollier, C. 81:427 Bertrand, J.C., see Tardy, B. 83:153 Caen, J.P., see André, P. 83:127 Bessos, H., A. Atkinson, A. McGill, J. Baillie, J. Seghatchian, M. Callas, D., see Hayes, J.M. 82:187 Vickers, D. Bishop, N. Tandy, W.G. Murphy. Apheresis platelet , see Yang, L.H. 81:555 concentrates: correlation of day one levels of in vitro quality Callas, D.D., J. Fareed. Comparative studies on the antithrombin markers with corresponding levels on days two to five of stor- potency of various thrombin inhibitors, as determined by using age. $4:367 an amidolytic method. 83:97 Bessos, H., see Huggan, P.J. 81:339 . Comparative anticoagulant effects of various thrombin Bevers, E.M., see Smeets, E.F. 81:419 inhibitors, as determined in the ecarin clotting time method. Bianchini, P., see Mascellani, G. 84:21 $3:463 Bichler, J., J.A. Heit, W.G. Owen. Detection of thrombin in Camerer, E., A.-B. Kolst¢, H. Prydz. Cell biology of tissue factor, the principal initiator of blood coagulation. 81:1 human blood by ex-vivo hirudin. 84:289 Canova, N., see Dettori, A.G. 83:103 Biggerstaff, J.P., see Amirkhosravi, A. 84:323 Cardigan, R.A., I.J. Mackie, S.J. Machin. The effect of heparin Billett, H.H., see Kheiri, S.A. 82:43 Binder, B.R., see Grubic, N. 84:431 and its neutralisation on functional assays for factor VIIa, factor VII and TFPI. 84:237 , see Zehetgruber, M. 83:143 Carmena, R., see Martinez, M. 83:375 Biondi, G., see Marongiu, F. 84:379 Casania, P., see Jorquera, J.1. 82:217 Bishop, D., see Bessos, H. 84:367 Casey, M.C., P.T. Murphy, V. Mitchell, J. Lunec. Specific markers Bloch, M.F., see Gerotziafas, G.T. 81:491 of bone formation in total protein S deficient patients (Letter Blomback, B. Fibrinogen and fibrin—proteins with complex roles to the Editors-in-Chief). 84:223. Correction. 84:482 in hemostasis and thrombosis. 83:1 Cavalli, E., see Cignarella, A. 84:311 Walter H. Seegers—An appreciation (Obituary). 84:305 Cavalot, F., see Anfossi, G. 82:57 , see Bark, N. 81:623 Cazenave, J.-P., see Kretz, J.-G. 84:391 Boddi, M., D. Prisco, S. Fedi, A.P. Cellai, A.A. Liotta, E. Parretti, Cella, G., U. Vertolli, A. Naso, A. Vianello, E. Rampin, A. Sbarai, F. Mecacci, G. Mello, R. Abbate. Antiphospholipid antibodies G. Boeri, W.E. Strauss. Tissue factor pathway inhibitor (TFPI) and pregnancy disorders in women with insulin dependent dia- activity in uremic patients during hemodialysis. 81:671 betes. 82:207. Correction. 84:299 Cellai, A.P., see Boddi, M. 82:207 Boddi, V., see Martini, F. 83:299 , see Chiarantini, E. 82:137 Boeri, G., see Cella, G. 81:671 , see Comeglio, P. 84:199 Bohgaki, M., see Wanaka, K. 82:79 , see Martini, F. 83:299 Bompiani, G., see Avellone, G. 81:277 Chabielska, E., V. Kolpakov, M.C. D’Adamo, A. De Curtis, W. Bonnar, J., see Norris, L.A. 81:407 Buczko, L. Iacoviello, M.B. Donati. Morphological and hemo- Bonneau, M., see Roussi, J. 81:297 static changes in rats with abdominal arterial prosthesis. 82:69 Borris, L.C., see Rahr, H.B. 81:607 Chabielska, E., see Mysliwiec, J. 83:175 Bostwick, J.S., C.J. Kasiewski, V. Chu, S.I. Klein, R.D. Sabatino, Chakfe, N., see Kretz, J.-G. 84:391 M.H. Perrone, C.T. Dunwiddie, J.J. Cook, R.J. Leadley, Jr. Chalas, J., see Keddad, K. 82:159 Author Index/Thrombosis Research 88 (1997) 509-520 511 Chang, B.-I., see Shi, G.-Y. 81:75 Davies, M.J. The contribution of thrombosis to the clinical expres- Chang, W.-C., see Shi, G.-Y. 81:75 sion of coronary atherosclerosis. 82:1 Cheung, W.-F., D.W. Stafford, T. Sugo. Localization of a calcium- de Castellarnau, C., see Pich, I. 82:323 dependent epitope to the amino terminal region of the Gla De Curtis, A., see Chabielska, E. 82:69 domain of human factor IX. 81:65 Dehmer, G.J., see Melton, L.G. 83:265 Chevallier, C., see Bal dit Sollier, C. 81:427 De La Cruz, J.P., A. Moreno, F. Mérida, J. Garcia Campos, F. Chiang, T.M. Effect of monoclonal antibody on the adhesion of Sanchez de la Cuesta. The pyrimido-pyrimidine derivatives, platelets to aortic segments. 84:345 dipyridamole, mopidamol and RA-642, prevent from retinal Chiang, T.M., E.S. Kang, A.H. Kang. Involvement of phosphopro- vascular defects in experimental diabetes mellitus. 81:327 tein phosphatase 1 in collagen-platelet interaction. 84:399 De La Cruz, J.P., see Gonzalez-Correa, J.A. 81:367 Chiarantini, E., R. Valanzano, A.A. Liotta, A.P. Cellai, S. Fedi, Delattre, J., see Bastard, J.-P. 81:271 I. Ilari, D. Prisco, F. Tonelli, R. Abbate. Hemostatic abnormali- de Maat, M., see Myrup, B. 81:485 ties in inflammatory bowel disease. 82:137 Demiroglu, H., I. Barista, S. Diindar. Assessing the risk of deep Chiarantini, E., see Comeglio, P. 84:199 vein thrombosis in Behcet’s disease (Letter to the Editors-in- , see Martini, F. 83:299 Chief). 84:297 Chiu, L., see Faung, S.-T. 81:91 Dempfle, C.-E., see Vogel, G. 81:241 Chong, B.H., see Vun, C.M. 81:525 Denson, K.W.E., M.E. Haddon, S.V. Reed, S. Davidson, T.J. Chou, T.-C., L.-Y. Hsu, M.-H. Yen, Y.-A. Ding. The inhibitory Littlewood. A more discriminating test for APC resistance and a effect of 2-thienyl 2’-hydroxyphenyl ketone (C85) on platelet possible screening test to include protein C and protein S. 81:151 thromboxane formation. 84:83 de Romeuf, C., C. Mazurier. Interest of a simple and fast method Christ, G., see Zehetgruber, M. 83:143 for platelet von Willebrand factor characterization. 83:287 Chu, V., see Bostwick, J.S. 82:495 De Simone, R., see Avellone, G. 81:277 Cicala, C., see Itoh, H. 83:405 Dettori, A.G., V. Zamboni, C. Manotti, N. Canova, M. Barbanti, Cierniewski, C.S., E. Pluskota, M. Cieslak, T. Brodniewicz, M. E. Palazzini. Pharmacology of a new low molecular weight Nowotarski. Antigenic properties of fibrinogen component of dermatan sulphate (Desmin) in healthy volunteers: repeated Hemaseel™ HMN subjected to the antiviral severe dry heat daily intramuscular administration of 400 mg for a week. 83:103 Devitt, M., see Norris, L.A. 81:407 treatment. 82:349 Dhall, D.P., see van Gelder, J.M. 82:33 Cieslak, M., see Cierniewski, C.S. 82:349 Di Garbo, V., see Avellone, G. 81:277 Cignarella, A., M. Nastasi, E. Cavalli, L. Puglisi. Novel lipid- Dilley, A., see Hooper, W.C. 81:577 lowering properties of Vaccinium myrtillus L. leaves, a tradi- Ding, Y.-A., see Chou, T.-C. 84:83 tional antidiabetic treatment, in several models of rat dyslipi- Di Nucci, G.D., see Coniglio, M. 83:183 daemia: a comparison with ciprofibrate. 84:311 Djurhuus, C., see Knudsen, L. 84:45 Cines, D., see Higazi, A.A.-R. 84:243 Dolara, A., see Martini, F. 83:299 Clausen, T., see Andersson, T. 82:109 Donati, M.B., see Chabielska, E. 82:69 Cloherty, T., E.A. Golden, S.E. Lind. Use of a modified activated Dorner, F., see Fischer, B.E. 81:157, 84:55 partial thromboplastin time to detect lupus anticoagulants. Douglas, G.J., see Itoh, H. 83:405 83:137 Doutremepuich, C., F. Azougagh Oualane, F. Doutremepuich, J. Col-De Beys, C., see Schlit, A.-F. 84:203 Fareed. New class of heparin derivatives with a potent anti- Comeglio, P., S. Fedi, A.A. Liotta, A.P. Cellai, E. Chiarantini, thrombotic effect and a very limited hemorrhagic activity. D. Prisco, F. Mecacci, E. Parretti, G. Mello, R. Abbate. Blood 83:217 clotting activation during normal pregnancy. 84:199 Doutremepuich, C., see Belougne, E. 82:453, 84:189, 207 Comfurius, P., see Smeets, E.F. 81:419 , see Imbault, P. 82:469 Coniglio, M., A. Platania, G.D. Di Nucci, P. Arcieri, R.M odzrew- , see Inamo, J. 83:229 ska, G. Mariani. Antiphospholipid-protein antibodies are not Doutremepuich, F., see Belougne, E. 82:453, 84:189, 207 an uncommon feature in retinal venous occlusions. 83:183 Doutremepuich, F., see Doutremepuich, C. 83:217 Cook, J.J., see Bostwick, J.S. 82:495 Doutremepuich, F., see Imbault, P. 82:469 Coppola, R., see Bottasso, B. 81:345 Drasin, T., M. Sahud. Blood-type and age affect human plasma Cordova, C., see Basili, S. 84:279 levels of histidine-rich glycoprotein in a large population. 84:179 Cordova, R., see Avellone, G. 81:277 Drohan, W.N., see Lee, T.K. 82:225 Cox, D., see Aoki, T. 81:439 Drouet, L., see Bal dit Sollier, C. 81:427 Crain, E.J., Jr., see Wong, P.C. 83:117 , see Roussi, J. $1:297 Cunningham, D., see Finch, C.N. 81:679 Drouet, L.O., see André, P. 83:127 Curats, R., see Jorquera, J.1. 82:217 Drouet, V., see André, P. 83:127 Droy-Lefaix, M.T., see Belougne, E. 82:453 Dachary-Prigent, J., see Pasquet, J.-M. 82:509 Diindar, S., see Demiroglu, H. 84:297 , see Ozdemir, O. 84:121 D’ Adamo, M.C., see Chabielska, E. 82:69 Dahlback, B., see Zéller, B. 83:475 Dunwiddie, C.T., see Bostwick, J.S. 82:495 Dandona, P., K. Thusu, U. Khurana, J. Love, A. Aljada, S. Mousa. Calcium, calmodulin and protein kinase C dependence of plate- Edlinger, G., S. Gallistl, W. Muntean. Lupus anticoagulant and let shape change. 81:163 factor XII activity in children with prolonged PTT. 83:403 Daniel, J.L., see Strouse, R.J. 82:485 Edwards, C.M., J.A. May, S. Heptinstall, K.C. Lowe. Effects of Danielsen, D., see Rahr, H.B. 81:607 Pluronic® F-68 (Poloxamer-188) on platelet aggregation in Davidson, D.J., see Burke, S.E. 83:421 human whole blood (Letter to the Editors-in-Chief). 81:511 Davidson, S., see Denson, K.W.E. 81:151 Efthimiou, Y., see Pirich, C. 81:213 Davies, J.A., see Hughes, J.R. 84:217 Eibl, J., see Fischer, B.E. 84:55 Author Index/Thrombosis Research 88 (1997) 509-520 Elikowski, W., see Lewandowski, K. 81:615 ogen mRNA and antigen co-present in human trophoblasts in Elsayed, Y.A., see Kato, K. 82:335 situ: possible implications. 81:263 Emri, S., see Ozdemir, O. 84:121 Gallistl, S., see Edlinger, G. 83:403 Ernofsson, M., A. Siegbahn. Platelet-derived growth factor-BB Garcia Campos, J., see De La Cruz, J.P. 81:327 and monocyte chemotactic protein-! induce human peripheral Garfinkel, L., see Gralnick, H.R. 81:113 blood monocytes to express tissue factor. 83:307 Garfinkel, L.I., see André, P. 83:127 Evans, S., see Vun, C.M. 81:525 Gawaz, M., A. Reininger, F.-J. Neumann. Platelet function and Evatt, B.L., see Benson, J.M. 83:87 platelet-leukocyte adhesion in symptomatic coronary heart dis- , see Hooper, W.C. 81:315, 577 ease. Effects of intravenous magnesium. 83:341 , see Phillips, D.J. 81:307 Gazzaniga, P.P., see Basili, S. 84:279 Ezban, M., see Holst, J. 81:461 Gensini, G.F., S. Micheli, D. Prisco, R. Abbate. Menopause and risk of cardiovascular disease. 84:1] Gensini, G.F., see Martini, F. 83:299 Fareed, J., see Callas, D.D. 83:97, 463 Gerotziafas, G.T., L. Bara, M.F. Bloch, P.E. Makris, M.M. Sa- , see Doutremepuich, C. 83:217 mama. Treatment with LMWHs inhibits factor VIla generation , see Hayes, J.M. 82:187 during in vitro coagulation of whole blood. 81:491 , see Kaiser, B. 82:257 Giddings, J.C., see Sawamoto, Y. 83:279 , see Yang, L.H. 81:555, 84:167 Gil, L., see Martinez, M. 83:375 Fasy, T.M., see Kheiri, S.A. 82:43 Godal, H.C., see Bach-Gansmo, E.T. 82:177 Fatah, K., see Bark, N. 81:623 Gokgay, E., see Tanindi, §. 81:471 Faung, S.-T., L. Chiu, C.-T. Wang. Platelet lysis and functional Golanski, J., T. Pietrucha, Z. Baj, J. Greger, C. Watala. Molecular perturbation by 13-methyl myristate. The major fatty acid in insights into the anticoagulant-induced spontaneous activation Flavobacterium ranacida. 81:91 of platelets in whole blood—various anticoagulants are not Fedi, S., see Boddi, M. 82:207 equal. 83:199 , see Chiarantini, E. 82:137 Golden, E.A., see Cloherty, T. 83:137 , see Comeglio, P. 84:199 Gonzalez-Correa, J.A., J.P. De La Cruz, M.I. Lucena, F. Sanchez , see Martini, F. 83:299 de la Cuesta. Effect of cyclosporin A on platelet aggregation and Feigen, L.P., see Pueyo, C. 81:101 thromboxane/prostacyclin balance in a model of extrahepatic Fernandez, M.A., see Jorquera, J.1. 82:217 cholestasis in the rat. 81:367 Ferro, L., see Fisher, J. 81:55 Gori, A.M., see Martini, F. 83:299 Ferroni, P., see Basili, S. 84:279 Goto, S., S. Handa, E. Takahashi, $. Abe, M. Handa, Y. Ikeda. Fiat, A.-M., see Bal dit Sollier, C. 81:427 Synergistic effect of epinephrine and shearing on platelet activa- Finch, C.N., V.A. Lyle, D. Cunningham, J.L. Miller. Expression tion. 84:35] of human platelet glycoprotein [bf in insect cells. 81:679 Goto, Y., see Sakata, T. 81:687 Fischer, B.E., G. Kramer, A. Mitterer, L. Grillberger, M. Reiter, Gouault-Heilmann, M., C. Leroy-Matheron. Factor V Leiden- W. Mundt, F. Dorner, J. Eibl. Effect of multimerization of dependent APC resistance: improved sensitivity and specificity human and recombinant von Willebrand factor on platelet ag- of the APC resistance test by plasma dilution in factor gregation, binding to collagen and binding of coagulation factor V-depleted plasma (Letter to the Editors-in-Chief). 82:281 VIII. 84:55 Graf, J., see Reininger, C.B. 81:641, 82:523 Fischer, B.E., A. Mitterer, F. Dorner. Qualitative and quantitative Gralnick, H.R., W.S. Kramer, L.P. McKeown, L. Garfinkel A. detection of human and recombinant thrombin by binding to Pinot, S.B. Williams, H. Krutzsch. Platelet adhesion at high leech and recombinant hirudin immobilized at the solid shear rates: the roles of von Willebrand factor/GPIb and the phase. 81:157 8, integrin aB;. 81:113 Fisher, J., T.K. Holland, R. Pescador, R. Porta, L. Ferro. Study Gram, J., see Myrup, B. 81:485 on pharmacokinetics of radioactive labelled defibrotide after Grau, A.J., F. Buggle, H. Becher, E. Werle, W. Hacke. The associ- oral or intravenous administration in rats. 81:55 ation of leukocyte count, fibrinogen and C-reactive protein with Fliedner, M., see Vielhaber, H. 81:651 vascular risk factors and ischemic vascular diseases. 82:245 Flynn, P.D., see Rota, S. 83:329 Greger, J., see Golanski, J. 83:199 Francis, D.A., see Amirkhosravi, A. 84:323 Greinacher, A., see Reininger, C.B. 81:641 Francis, J.L., see Amirkhosravi, A. 84:323 Grillberger, L., see Fischer, B.E. 84:55 Fujii, N., T. Kaji, C. Yamamoto, Y. Fujiwara, F. Koizumi. Phorbol Groscolas, R., see Péschl, J.M.B. 81:283 12-myristate 13-acetate stimulates the release of glycosamino- Grubic, N., M. Stegnar, P. Peternel, A. Kaider, B.R. Binder. A glycans from cultured vascular endothelial cells: possible novel G/A and the 4G/5G polymorphism within the promoter involvement of protein kinase C activation. 82:379 of the plasminogen activator inhibitor-1 gene in patients with Fujitani, K., see Ikeda, M. 82:87 deep vein thrombosis. 84:431 Fujiwara, Y., see Fujii, N. 82:379 Grunebaum, L., see Kretz, J.-G. 84:391 , see Kaji, T. 82:389 Gu, J., see Xia, L. 81:477 Fukutake, K., see Ikematsu, S. 82:129 Guo, Y., see Kessler, C. 84:145 Funatsu, A., see Kamikubo, Y.-i. 83:161 Guyotat, D., see Tardy, B. 83:153 Furlan, M., see Steinmann, C. 81:145 Hachiya, T., see Rydzewski, A. 84:445 Gabriel, D.A., see Melton, L.G. 83:265 Hacke, W., see Grau, A.J. 82:245 Gabriel, H., see Zehetgruber, M. 83:143 Haddeland, U., see Bennick, A. 82:169 Gaffney, P.J., see Boutcher, P.A. 81:231 Haddon, M.E., see Denson, K.W.E. 81:151 , see Raut, S. 81:503 Hainaud, P., see André, P. 83:127 Galanakis, D.,G. Nuovo, S. Spitzer, C. Kaplan, I. Scharrer. Fibrin- Hainque, B., see Bastard, J.-P. 81:271 Author Index/Thrombosis Research 88 (1997) 509-520 513 Halvorsen, S., see Bach-Gansmo, E.T. 82:177 support human factor VII autoactivation in the absence of tissue Hamers, M.J.A.G., see Stephens, R.W. 84:453 factor. 82:119 Hamuro, T., see Kamikubo, Y.-i. 83:161 Ikeda, M., J.-i. Kambayashi, S.-i. lwamoto, N. Shinoki, T. Naka- Hamwi, A., see Veitl, M. 82:399 mura, K. Okahara, K. Fujitani, T. Shibuya, T. Kawasaki, M. Handa, M., see Goto, S. 84:351 Monden. Hemostasis activation during sclerotherapy of lower Handa, S., see Goto, S. 84:351 extremity varices. 82:87 Hasenkam, J.M., see Knudsen, L. 84:45 Ikeda, M., T. Onda, I. Tomita, T. Tomita. The differences in Ca’*- Hayashi, K., see Sawamoto, Y. 83:279 sensitivity of protein kinase C in platelets from Wistar Kyoto Hayes, J.M., W. Jeske, D. Callas, O. Iqbal, J. Fareed. Comparative rat and stroke-prone spontaneously hypertensive rat. 82:417 intravenous antithrombotic actions of heparin and site directed Ikeda, Y., see Goto, S. 84:351 thrombin inhibitors in a jugular vein clamping model. 82:187 Ikematsu, S., K. Fukutake, N. Aoki. Heterozygote for plasmin Hedner, U., see Holst, J. 81:461 inhibitor deficiency developing hemorrhagic tendency with ad- Heikkila, J., see Peltonen, S. 82:459 vancing age. 82:129 Heit, J.A., see Bichler, J. 84:289 Ilari, I., see Chiarantini, E. 82:137 Henkin, J., see Burke, S.E. 83:421 Imbault, P., F. Doutremepuich, O. Aguejouf, C. Doutremepuich. Henriksson, A.E., T.K. Nilsson, U. Jansson, D. Bergqvist. Experi- Antithrombotic effects of aspirin and LMWH in a laser-induced mental haemorrhage and blood component transfusion in hu- model of arterials and venous thrombosis. 82:469 mans: no change in plasma concentration of thrombin-anti- Imbault, P., see Belougne, E. 82:453 thrombin complex and plasmin-antiplasmin complex. 82:409 Inada, M., see Kaji, T. 82:389 Heptinstall, S., see Edwards, C.M. 81:511 Inamo, J., E. Belougne, C. Doutremepuich. Importance of photo Heran, C.L., see Schumacher, W.A. 81:187 activation of Rose Bengal for platelet activation in experimental Herbert, J.M., see Yang, L.H. 81:555 models of photochemically induced thrombosis. 83:229 Higazi, A.A.-R., D. Cines. Regulation of single chain urokinase lomhair, M.M., S.M. Lavelle. Effect of aspirin-dipyridamole and by small peptides. 84:243 heparin and their combination on venous thrombosis in hyper- Hijikata-Okunomiya, A., see Wanaka, K. 82:79 coagulable or thrombotic animals. 82:479 Hoagland, L.E., D.A. Triplett, F. Peng, L. Barna. APC-resistance lomhair, M.M., see Lavelle, S.M. 84:411 as measured by a Textarin time assay: comparison to the APTT- Iqbal, O., see Hayes, J.M. 82:187 based method. 83:363 , see Yang, L.H. 84:167 Hoffman, M., see Sumner, W.T. 81:533 Itoh, H., C. Cicala, G.J. Douglas, C.P. Page. Platelet accumulation Hggdahl, H., see Andersson, T. 82:109 induced by bacterial endotoxin in rats. 83:405 Holland, T.K., see Fisher, J. 81:55 Iversen, L.H., O. Thorlacius-Ussing. Short-time stability of mark- Holloway, B.P., see Benson, J.M. 83:87 ers of coagulation and fibrinolysis in frozen plasma. 81:253. Holme, S., see Owens, M.R. 81:177 Correction. 82:199 Holst, J., B. Lindblad, G. Westerlund, C. Bregengaard, M. Ezban, . Markers of fibrin formation in colorectal surgery: fibrino- P.B. Ostergaard, O. Nordfang, U. Hedner. Pharmacokinetics peptide A and soluble fibrin. 81:569 and delayed experimental anti-thrombotic effect of two domain Iversen, N., P.M. Sandset, U. Abildgaard, P.A. Torjesen. Binding non-glycosylated tissue factor pathway inhibitor. 81:461 of tissue factor pathway inhibitor to cultured endothelial cells— Hooper, W.C., A. Dilley, M.J.A. Ribeiro, J. Benson, H. Austin, influence of glycosaminoglycans. 84:267 V. Silva, P. Rawlins, N.K. Wenger, B.L. Evatt. A racial differ- Iwamoto, S.-i., see Ikeda, M. 82:87 ence in the prevalence of the Arg506—Gln mutation. 81:577 Iwan-Zietek, I., see Zietek, Z. 83:399 Hooper, W.C., D.J. Phillips, B.L. Evatt. TNF-a suppresses IL-6 Izquierdo, C., see Bal dit Sollier, C. 81:427 upregulation of protein S in HepG-2 hepatoma cells. 81:315 Hooper, W.C., see Benson, J.M. 83:87 Jacobsen, E.M., P.M. Sandset, F. Wislgff. Lupus anticoagulant , see Phillips, D.J. 81:307 and a functional assay for tissue factor pathway inhibitor (Letter Hoppensteadt, D.A., see Yang, L.H. 84:167 to the Editors-in-Chief). 83:339 Horie, N., see Wanaka, K. 82:79 Jacobsen, E.M., F. Wislgff. False negative screening tests for lupus Hoshide, S., see Katsuura, Y. 82:147 anticoagulants—an unrecognized problem?. 82:445 Hsu, L.-Y., see Chou, T.-C. 84:83 Jansson, U., see Henriksson, A.E. 82:409 Huber, K., see Zehetgruber, M. 83:143 Jardel, C., see Bastard, J.-P. 81:271 Huggan, P.J., A.A. Milne, H. Bessos, A. Atkinson, W.G. Murphy. Jen, C.J., see Shi, G.-Y. 81:75 Plasma glycocalicin levels are not elevated in patients with a Jepsson, J.-O., see Zoller, B. 83:475 history of transient ischaemic event and are normal in aspi- Jeske, W., see Hayes, J.M. 82:187 rinated normal volunteers. 81:339 Jespersen, J., see Marckmann, P. 82:439 Hughes, J.R.,J.A. Davies, C.R.M. Prentice. The effect of different , see Myrup, B. 81:485 microtitre plates on the enzyme-linked immunosorbent assay Johansen, H.T., see Karlsrud, T.S. 82:265 (ELISA) for anticardiolipin antibodies (ACAs). 84:217. Correc- Jollés, P., see Bal dit Sollier, C. 81:427 tion. 84:48] Jorquera, J.I.,J. Aznar, M.A. Fernandez, J.M. Montoro, R. Curats, Hughes, P., see Knudsen, L. 84:45 P. Casafia. A modification of the APC resistance test and its application to the study of patients on coumarin therapy. 82:217 Jungo, M., see Steinmann, C. 81:145 lacoviello, L., see Chabielska, E. 82:69 Jiirgens, H., see Nowak-Gottl, U. 81:665 Iguchi, A., see Naito, M. 84:129 Jyu-ri, K., see Kamikubo, Y.-i. 83:161 Iguchi, K., S. Murakami, A. Matsumoto, A. Shimizu, N. Sakura- gawa. Abnormally high level of antithrombin in a case with hepatocellular carcinoma. 84:137 Kaider, A., see Grubic, N. 84:431 lino, M., W. Kisiel. Sphingosine-containing phospholipid vesicles Kaiser, B., M. Koza, J.M. Walenga, J. Fareed. Flow cytometric Author Index/Thrombosis Research 88 (1997) 509-520 evaluation of the effect of various thrombin inhibitors on plate- in vitro: possible implications in the antiphospholipid syn- let activation in whole blood. 82:257 drome. 82:43 Kaji, T., M. Inada, C. Yamamoto, Y. Fujiwara, F. Koizumi. Cyclic Khurana, U., see Dandona, P. 81:163 AMP-dependent pathway that mediates suppressive regulation Kisiel, W., see lino, M. 82:119 of glycosaminoglycan production in cultured vascular endothe- Kitazato, K., K.T. Kitazato, H. Nagase, K. Minamiguchi. DHG, lial cells. 82:389 a new depolymerized holothurian glycosaminoglycan, exerts an Kaji, T., see Fujii, N. 82:379 antithrombotic effect with less bleeding than unfractionated or Kambayashi, J.-i., N. Shinoki, T. Nakamura, H. Ariyoshi, T. Kawa- low molecular weight heparin, in rats. 84:111 saki, M. Sakon, M. Monden. Prevalence of impaired respon- Kitazato, K., see Minamiguchi, K. 83:253 siveness to epinephrine in platelets among Japanese. 81:85 Kitazato, K.T., see Kitazato, K. 84:111 Kambayashi, J.-i., see Ikeda, M. 82:87 , see Minamiguchi, K. 83:253 Kamei, S., see Kamikubo, Y.-i. 83:161 Kiyoki, M., see Katsuura, Y. 82:147 Kamikubo, Y.-i., T. Hamuro, J.-i. Matsuda, S. Kamei, K. Jyu-ri, S. Klein, S.I., see Bostwick, J.S. 82:495 Miyamoto, A. Funatsu, H. Kato. The clearance of proteoglycan- Kluft, C., see Myrup, B. 81:485 associated human recombinant tissue factor pathway inhibitor Knofler, R., G. Weissbach, E. Kuhlisch. Critical evaluation of the (H-RTFPI) in rabbits: a complex formation of H-RTFPI with quantification of ATP release reaction in whole blood. 84:157 factor Xa promotes a clearance rate of H-RTFPI. 83:16] Knofler, R., see Malyszko, J. 81:397 Kamisue, S., see Sawamoto, Y. 83:279 Knudsen, L., J.M. Hasenkam, H.H. Kure, P. Hughes, L. Bellaiche, Kanazuka, M., T. Shigekiyo, N. Toibana, S. Saito. Increase in P. Ahlburg, C. Djurhuus. Monitoring thrombin generation with plasma thrombomodulin level in patients with vibration syn- prothrombin fragment 1.2 assay during cardiopulmonary bypass drome. 82:51 surgery. 84:45 Kaneko, H., see Rydzewski, A. 84:445 Koch, H.G., see Vielhaber, H. 81:651 Kang, A.H., see Chiang, T.M. 84:399 Kohlhase, B., see Nowak-Gottl, U. 81:665 Kang, E.S., see Chiang, T.M. 84:399 , see Vielhaber, H. 81:651 Koizumi, F., see Fujii, N. 82:379 Kaplan, C., see Galanakis, D. 81:263 Karakoca, Y., see Ozdemir, O. 84:121 , see Kaji, T. 82:389 Kojima, T., see Yamazaki, T. 82:275 Karanikas, G., see Schmid, P. 81:451 Koéko§lu, E., see Siier, S. 83:77 Kario, K., see Sakata, T. 81:687, 82:235 Kolpakov, V., see Chabielska, E. 82:69 Karlsrud, T.S., L. Bug, A.O. Aasen, H.T. Johansen. Quantification Kolstg, A.-B., see Camerer, E. 81:1 of kininogens in plasma. A functional method based on the Koéseoglu, V., see Tanindi, §. 81:471 cysteine proteinase inhibitor activity. 82:265 Kotschy, M., see Zietek, Z. 83:399 Kasiewski, C.J., see Bostwick, J.S. 82:495 Koza, M., see Kaiser, B. 82:257 Katayama, Y., see Sakata, T. 81:687, 82:235 Krailadsiri, P., J. Seghatchian. Negatively charged leucocyte filter Kato, H., see Kamikubo, Y.-i. 83:161 significantly enhances kallikrein and thrombin-like activities of , see Sakata, T. 81:687, 82:235 platelet concentrates. 83:469 Kato, K., Y.A. Elsayed, M. Namoto, K. Nakagawa, K. Sueishi. Kramer, G., see Fischer, B.E. 84:55 Enhanced expression of tissue factor activity in the atheroscle- Kramer, W.S., see Gralnick, H.R. 81:113 rotic aortas of cholesterol-fed rabbits. 82:335 Kretz, J.-G., N. Chakfe, M.-L. Wiesel, L. Grunebaum, V. Zam- Katsumi, A., see Yamazaki, T. 82:275 boni, E. Palazzini, J.-P. Cazenave. The treatment of deep vein Katsuura, Y., T. Mochizuki, M. Tamura, S. Hoshide, M. Kiyoki, thrombosis with continuous intravenous low-molecular-weight T. Nakagaki, S. Miyamoto. Species specificity of anticoagulant dermatan sulphate (Desmin). A pilot study. 84:39] activity of activated human protein C. Involvement of factor Kritz, H., see Schmid, P. 81:451 V as well as protein S. 82:147 , see Sinzinger, H. 84:475 Katsuura, Y., S. Okamoto, N. Ohno, K. Wanaka. Effects of a Krutzsch, H., see Gralnick, H.R. 81:113 highly selective synthetic inhibitor of plasma kallikrein on dis- Kuhlisch, E., see Knéfler, R. 84:157 seminated intravascular coagulation in rats. 82:361 Kume, S., see Qi, R. 81:43 Kawabata, A. 1H-[1,2,4Joxadiazolo[4,3-a]quinoxalin-l-one re- , see Satoh, K. 81:515 verses the inhibition by sodium nitroprusside of thrombin- Kure, H.H., see Knudsen, L. 84:45 induced platelet aggregation in the rat (Letter to the Editors- Kirekci, A.E., see Tanindi, §. 81:471 in-Chief). 82:543 Kurota, K., see Qi, R. 81:43 Kawasaki, T., see Ikeda, M. 82:87 Kurtaran, A., see Veitl, M. 82:399 , see Kambayashi, J.-i. 81:85 Kushimoto, S., K. Okajima, M. Uchiba, K. Murakami, H. Okabe, Kaya, S.U., see Ugurman, F. 84:295 K. Takatsuki. Pulmonary vascular injury induced by hemor- Kececioglu, D., see Vielhaber, H. 81:651 rhagic shock is mediated by P-selectin in rats. 82:97 Keddad, K., S.M. Razavian, Ch. Baussan, A. Abella, J. Chalas, Kiisters, B., see Storck, J. 84:463 J. Levenson, A. Simon, N. Moatti, A. Legrand. Decreased eryth- rocyte deformability in glycogen storage disease. 82:159 Lacroix, K.A., C. Bean, L. Box, K. Wagner. A study of the fibrino- Kehl, H.G., see Vielhaber, H. 81:651 lytic response in healthy men and women following a brief Kehrel, B., see Vielhaber, H. 81:651 exposure to venous occlusion. 81:133 Kelly, K.E., see Syed, S. 84:419 Lammle, B., see Steinmann, C. 81:145 Kessler, C., R. Mitusch, Y. Guo, A. Rosengart, A. Sheikhzadeh. Lamponi, S., see Magnani, A. 81:383 Embolism from the aortic arch in patients with cerebral isch- Laporte, A., see Roussi, J. 81:297 emia. 84:145 Laporte-Simitsidis, S., see Tardy, B. 83:153 Kheiri, S.A., T.M. Fasy, H.H. Billett. Effects of H1 histones and Lassen, M.R., see Rahr, H.B. 81:607 a monoclonal autoantibody to H1 histones on clot formation Lasser, R., see Reininger, C.B. 81:641 Author Index/Thrombosis Research 88 (1997) 509-520 515 Lassila, R., see Peltonen, S. 82:369, 459 fibrinolysis, peripheral serotonergic system and serum lipids in Lavelle, S.M.,M.M. lomhair. The quantitative reduction by acute- Japanese monkeys. 81:397 dose warfarin of venous thrombosis in normal and hyperthrom- Malyszko, J., see Pawlak, D. 83:189 botic rats. 84:411 Malyszko, J.S., see Malyszko, J. 83:351 Lavelle, S.M., see lomhair, M.M. 82:479 , see Pawlak, D. 83:189 Lavenne-Pardonge, E., see Schlit, A.-F. 84:203 Mameli, G., see Barcellona, D. 81:403 Leadley, R.J., Jr., see Bostwick, J.S. 82:495 Mammen, E.F. Walter H. Seegers 1910-1996 (Obituary). 84:303 Lee, T.K., N. Bangalore, W. Velander, W.N. Drohan, H. Lubon. Mannucci, P.M., see Bottasso, B. 81:345 Activation of recombinant human protein C. 82:225 Manotti, C., see Dettori, A.G. 83:103 Legrand, A., see Keddad, K. 82:159 Marckmann, P., P. Nawroth, P. Wahl, J. Jespersen. Diet, gender, Leksell, H., see Z6ller, B. 83:475 and plasma thrombomodulin. 82:439 Lentz, S.R., see Newell, A.A. 84:373 Mari, D., see Bottasso, B. 81:345 Lepdntalo, M., see Peltonen, S. 82:369 Mariani, G., see Coniglio, M. 83:183 Leray, C., see Péschl, J.M.B. 81:283 Marongiu, F., G. Biondi, D. Barcellona, M.L. Vannini, A. Bales- Leroy-Matheron, C., see Gouault-Heilmann. 82:281 trieri. The old manual tilt tube thrombotest: still useful in the Leskopf, W., see Vogel, G. 81:241 management of oral anticoagulants?. 84:379 Levenson, J., see Keddad, K. 82:159 Marongiu, F., see Barcellona, D. 81:403 Lewandowski, K., W. Elikowski, Z. Turowiecka, M. Zozulinska, Marti, R., see Martinez, M. 83:375 L. Przybyt, K. Zawilska. Low molecular weight heparin and Martinez, M., A. Vaya, R. Marti, L. Gil, I. Lluch, R. Carmena, the heparin mobilisable pool of platelet factor 4 are reduced J. Aznar. Erythrocyte membrane cholesterol/phospholipid in young survivors of myocardial infarction. 81:615 changes and hemorheological modifications in familial hyper- Lewandowski, K., Z. Turowiecka, J. Puszczewicz, S. Mackiewicz, cholesterolemia treated with lovastatin. 83:375 K. Zawilska. Antiphospholipid antibodies and disturbances of Martini, F., A. Zuppiroli, A.M. Gori, E. Chiarantini, S. Fedi, phospholipid dependent coagulation tests in patients with sys- D. Prisco, A.P. Cellai, V. Boddi, R. Abbate, A. Dolara, G.F. temic sclerosis and severe peripheral ischaemia (Letter to the Gensini. Platelet and blood clotting activation in patients with Editors-in-Chief). 81:693 mitral valve prolapse. 83:299 Li, P., see Xia, L. 81:477 Mascellani, G., L. Liverani, B. Parma, G.L. Bergonzini, P. Bian- Li, X.-B., see Wong, K. 81:219 chini. Active site for heparin cofactor II in low molecular mass Lin, M.T., see Shi, G.-Y. 81:75 dermatan sulfate. Contribution to the antithrombotic activity Lind, S.E., see Cloherty, T. 83:137 of fractions with high affinity for heparin cofactor II. 84:21 Lindblad, B., see Holst, J. 81:461 Massucco, P., see Anfossi, G. 82:57 Linderkamp, O., see Péschl, J.M.B. 81:283 Matsuda, J.-i., see Kamikubo, Y.-i. 83:161 Liotta, A.A., see Boddi, M. 82:207 Matsumoto, A., see Iguchi, K. 84:137 , see Chiarantini, E. 82:137 Matsuo, N., see Shinya, H. 81:195 , see Comeglio, P. 84:199 Matsuyama, T., see Sakata, T. 81:687, 82:235 Littlewood, T.J., see Denson, K.W.E. 81:151 Mattiello, L., see Anfossi, G. 82:57 Liu, Y., see Xia, L. 81:477 May, J.A., see Edwards, C.M. 81:511 Liverani, L., see Mascellani, G. 84:21 Mazurier, C., see de Romeuf, C. 83:287 Lluch, I., see Martinez, M. 83:375 McAndrew, P.E., J.T. Brandt, D.K. Pearl, T.W. Prior. The inci- Lo, S.K., see Simantov, R. 84:361 dence of the gene for thermolabile methylene tetrahydrofolate Lorentzen, B., see Andersson, T. 82:109 reductase in African Americans. 83:195 Love, J., see Dandona, P. 81:163 McGill, A., see Bessos, H. 84:367 Lowe, K.C., see Edwards, C.M. 81:511 McGuiness, J.A., see Selley, M.L. 83:449 Lubbers, N.L., see Burke, S.E. 83:421 McIntyre, J.A., see Sugi, T. 84:97 Lubon, H., see Lee, T.K. 82:225 McKeown, L.P., see Gralnick, H.R. 81:113 Lucena, M.I., see Gonzalez-Correa, J.A. 81:367 McLoughlin, P., see Boutcher, P.A. 81:231 Lunec, J., see Casey, M.C. 84:223 Mecacci, F., see Boddi, M. 82:207 Lyle, V.A., see Finch, C.N. 81:679 , see Comeglio, P. 84:199 Meehan, A., see Melton, L.G. 83:265 Machin, S.J., see Cardigan, R.A. 84:237 Mello, G., see Boddi, M. 82:207 Maciejewski, J.P., N.S. Young, M. Yu, S.M. Anderson, E.M. , see Comeglio, P. 84:199 Sloand. Analysis of the expression of glycosylphosphatidylinosi- Melton, L.G., G.J. Dehmer, D.A. Tate, K.M. Muga, A. Meehan, tol anchored proteins on platelets from patients with paroxys- D.A. Gabriel. Variable influence of heparin and contrast agents mal nocturnal hemoglobinuria. 83:433 on platelet function as assessed by the in vitro bleeding time. Mackie, I.J., see Cardigan, R.A. 84:237 $3:265 Mackiewicz, S., see Lewandowski, K. 81:693 Mérida, F., see De La Cruz, J.P. 81:327 Magnani, A., A. Albanese, S. Lamponi, R. Barbucci. Blood-inter- Mezzano, D., see Aranda, E. 84:67 action performance of differently sulphated hyaluronic acids. Micheli, S., see Gensini, G.F. 84:1 81:383 Mieszczak, C., K. Winther. Does warfarin enhance platelet activ- Makris, P.E., see Gerotziafas, G.T. 81:491 ity?. 84:285 Malyszko, J., J.S. Malyszko, D. Pawlak, K. Pawlak, W. Buczko, Mikkola, T., see Turunen, P. 81:635 M. Mysliwiec. Hemostasis, platelet function and serotonin in Miller, J.L., see Finch, C.N. 81:679 acute and chronic renal failure. 83:351 Millet, J., M. Vaillot, J. Theveniaux, N.L. Brown. Experimental Malyszko, J., T. Urano, R. Knéfler, Y. Takada, A. Takada. Effects venous thrombosis induced by homologous serum in the rat. of short-term treatment with mevalotin on platelet aggregation, $1:497 Author Index/Thrombosis Research 88 (1997) 509-520 Milne, A.A., see Huggan, P.J. 81:339 Naso, A., see Cella, G. 81:671 Minamiguchi, K., H. Nagase, K.T. Kitazato, K. Kitazato. Interac- Nastasi, M., see Cignarella, A. 84:311 tion of a new depolymerized holothurian glycosaminoglycan Nawroth, P., see Marckmann, P. 82:439 with proteins in human plasma. 83:253 Neumann, F.-J., see Gawaz, M. 83:341 Minamiguchi, K., see Kitazato, K. 84:111 Neumann, I., see Sinzinger, H. 84:475 Mitchell, V., see Casey, M.C. 84:223 Newell, A.A., T.J. Raife, S.R. Lentz. Interference in protein C Mitterer, A., see Fischer, B.E. 81:157, 84:55 activation assays from endogenous serpins in mammalian host Mitusch, R., see Kessler, C. 84:145 cells. 84:373 Miyamoto, S., see Kamikubo, Y.-i. 83:161 Nguan, O., see Wong, P.C. 83:117 , see Katsuura, Y. 82:147 Niiya, K., see Ozawa, T. 81:595 Miyata, T., see Sakata, T. 81:687, 82:235 Nikandrov, N.N., see Pyzhova, N.S. 82:303 Moatti, N., see Keddad, K. 82:159 Nikandrov, V.N., see Pyzhova, N.S. 82:303 Nilsson, A., see Xu, N. 81:203 Mochizuki, M., Y. Takada, T. Urano, N. Nagai, T. Nakano, K. Nakajima, A. Takada. The in vitro effects of chylomicron rem- Nilsson, J.-E., see Z6ller, B. 83:475 nant and very low density lipoprotein remnant on platelet aggre- Nilsson, T.K., see Henriksson, A.E. 82:409 gation in blood obtained from healthy persons. 81:583 Nomura, H., see Naito, M. 84:129 Mochizuki, T., see Katsuura, Y. 82:147 Norberg, K., see Salte, R. 83:389 Modzrewska, R., see Coniglio, M. 83:183 Nordfang, O., see Holst, J. 81:461 Monden, M., see Ikeda, M. 82:87 Norlund, L., see Z6dller, B. 83:475 , see Kambayashi, J.-i. 81:85 Norris, L.A., M. Devitt, J. Bonnar. The role of thromboxane A, in Monroe, D.M., see Sumner, W.T. 81:533 increased whole blood platelet aggregation in oral contraceptive Montoro, J.M., see Jorquera, J.1. 82:217 users. 81:407 Moreno, A., see De La Cruz, J.P. 81:327 Novinger, M.S., see Phillips, D.J. 81:307 Moriau, M., see Schlit, A.-F. 84:203 Nowak-Gottl, U., B. Kohlhase, H. Vielhaber, I. Aschka, R. Morrical, D., see Peng, F. 83:243 Schneppenheim, H. Jiirgens. APC resistance in neonates and Morser, J., see Ohlin, A.-K. 82:313 infants: adjustment of the APTT-based method. 81:665 Morys-Wortmann, C., see Storck, J. 84:463 Nowak-Gdttl, U., see Vielhaber, H. 81:651 Motoyama, Y., see Aoki, T. 81:439 Nowotarski, M., see Cierniewski, C.S. 82:349 Mousa, S., see Dandona, P. 81:163 Nowotny, C., see Ulm, M.R. 83:237 Mowinckel, M.-C., see Andersson, T. 82:109 Nuovo, G., see Galanakis, D. 81:263 Muga, K.M., see Melton, L.G. 83:265 Nurden, A.T., see Pasquet, J.-M. 82:509 Mularoni, E., see Anfossi, G. 82:57 Mundt, W., see Fischer, B.E. 84:55 O’Brien, J.R. Angiodysplasia, haemostasis and capillaries. A hy- Muntean, W., see Edlinger, G. 83:403 pothesis (Letter to the Editors-in-Chief). 84:385 Murakami, K., see Kushimoto, S. 82:97 Obwegeser, R., see Ulm, M.R. 83:237 Murakami, S., see Iguchi, K. 84:137 Mdegaard, O.R., see Salte, R. 83:389 Murphy, P.T., see Casey, M.C. 84:223 O’Grady, J., see Pirich, C. 81:213 Murphy, W.G., see Bessos, H. 84:367 O’Grady, J., see Sinzinger, H. 82:291, 84:475 , see Huggan, P.J. 81:339 Ohlin, A.-K., J. Morser, H. Ohlin. Soluble thrombomodulin anti- Myrup, B., M. de Maat, P. Rossing, J. Gram, C. Kluft, J. Jespersen. gen in plasma is increased in patients with acute myocardial Elevated fibrinogen and the relation to acute phase response infarction treated with thrombolytic therapy. 82:313 in diabetic nephropathy. 81:485 Ohlin, A.-K., see Xu, N. 81:203 Mysliwiec, J., A. Azzadin, E. Chabielska, A. Takada, M. Mysli- Ohlin, H., see Ohlin, A.-K. 82:313 wiec, W. Buczko. The effect of tacrolimus (FK506) and Ohno, N., see Katsuura, Y. 82:361 cyclosporin A (CyA) on peripheral serotonergic mechanisms , see Wanaka, K. 82:79 in uremic rats. 83:175 Okabe, H., see Kushimoto, S. 82:97 Mysliwiec, M., see Malyszko, J. 83:351 Okada, Y., see Wanaka, K. 82:79 , see Mysliwiec, J. 83:175 Okahara, K., see Ikeda, M. 82:87 , see Pawlak, D. 83:189 Okajima, K., see Kushimoto, S. 82:97 Okamoto, S., see Katsuura, Y. 82:361 Nagai, N., see Mochizuki, M. 81:583 , see Wanaka, K. 82:79 Nagase, H., see Kitazato, K. 84:111 Okamoto, U., see Wanaka, K. 82:79 , see Minamiguchi, K. 83:253 Olsson, P. Birger Blombiack: an appreciation on his seventieth Nair, C.H., see van Gelder, J.M. 82:33 birthday. 82:287 Naito, M., H. Nomura, A. Iguchi. Migration of cultured vascular Onda, T., see Ikeda, M. 82:417 smooth muscle cells into non-crosslinked fibrin gels. 84:129 Onde, G., see Ugurman, F. 84:295 Naito, T., see Wanaka, K. 82:79 O’Regan, R.G., see Boutcher, P.A. 81:231 Nakagaki, T., see Katsuura, Y. 82:147 Orning, L., see Rénning, H.F. 84:73 Nakagawa, K., see Kato, K. 82:335 , see Stephens, R.W. 84:453 Nakai, H., see Sawamoto, Y. 83:279 Orsel, O., see USurman, F. 84:295 Nakajima, K., see Mochizuki, M. 81:583 @Mstergaard, P.B., see Holst, J. 81:461 Nakamura, T., see Ikeda, M. 82:87 Owen, W.G., see Bichler, J. 84:289 , see Kambayashi, J.-i. 81:85 Owens, M.R.,S. Holme. Aurin tricarboxylic acid inhibits adhesion Nakano, T., see Mochizuki, M. 81:583 of platelets to subendothelium. 81:177 Namoto, M., see Kato, K. 82:335 Ozaki, Y., see Qi, R. 81:43 Author Index/Thrombosis Research 88 (1997) 509-520 517 , see Satoh, K. 81:515 Pirich, C., see Schmid, P. 81:451 Ozawa, T., K. Niiya, N. Sakuragawa. Absence of factor V Leiden , see Sinzinger, H. 82:291 in the Japanese (Letter to the Editors-in-Chief). 81:595 Platania, A., see Coniglio, M. 83:183 Ozcan, O., see Tanindi, §. 81:471 Ploeckinger, B., see Ulm, M.R. 83:237 Ozdemir, O., S. Emri, Y. Karakoca, N. Sayinalp, H. Akay, S. Pluskota, E., see Cierniewski, C.S. 82:349 Diindar, I. Baris. Fibrinolytic system in plasma and pleural fluid Pokhilko, A.V., see Zarnitsina, V.1. 84:225, 333 in malignant pleural mesothelioma. 84:121 Porquet, D., see Bastard, J.-P. 81:271 Porta, R., see Fisher, J. 81:55 Paczulski, R., see Zietek, Z. 83:399 Poéschl, J.M.B., C. Leray, R. Groscolas, P. Ruef, O. Linderkamp. Page, C.P., see Itoh, H. 83:405 Dietary docosahexaenoic acid improves red blood cell deform- Palazzini, E., see Dettori, A.G. 83:103 ability in rats. 81:283 , see Kretz, J.-G. 84:39] Prentice, C.R.M., see Hughes, J.R. 84:217 Paoletti, G., see Anfossi, G. 82:57 Prieto, C., see Aranda, E. 84:67 Parma, B., see Mascellani, G. 84:21 Prior, T.W., see McAndrew, P.E. 83:195 Parretti, E., see Boddi, M. 82:207 Prisco, D., see Boddi, M. 82:207 , see Comeglio, P. 84:199 , see Chiarantini, E. 82:137 Pasquet, J.-M., F. Toti, A.T. Nurden, J. Dachary-Prigent. Procoag- ———., see Comeglio, P. 84:199 ulant activity and active calpain in platelet-derived micropar- ———, see Gensini, G.F. 84:1 ticles. 82:509 , see Martini, F. 83:299 Pawlak, D., J. Malyszko, J.S. Malyszko, K. Pawlak, W. Buczko, Prydz, H., see Camerer, E. 81:1 M. Mysliwiec. Peripheral serotonergic system in uremia. 83:189 Przybyl, L., see Lewandowski, K. 81:615 Pawlak, D., see Malyszko, J. 83:351 Pueyo, C., J.J. Badimon, T. Royo, L.P. Feigen, L. Badimon. A Pawlak, K., see Malyszko, J. 83:351 mimetic of the RGDF-peptide [arginine-glycine-aspartic acid- , see Pawlak, D. 83:189 phenylalanine] blocks aggregation and flow-induced platelet Pearl, D.K., see McAndrew, P.E. 83:195 deposition on severely injured stenotic arterial wall. Effects on Peltonen, S., R. Lassila, J. Heikkila. Activation of coagulation different animal models and in humans. 81:101 and fibrinolysis despite heparinization during successful elective Puglisi, L., see Cignarella, A. 84:311 coronary angioplasty. 82:459 Pulcinelli, F.M., see Basili, S. 84:279 Peltonen, S., R. Lassila, M. Lepantalo. Increased circulating plas- Puszczewicz, J., see Lewandowski, K. 81:693 minogen activator inhibitor-1 in patients with patent femorodis- Pyzhova, N.S., V.N. Nikandrov, N.N. Nikandrov. Effect of active tal venous bypass. 82:369 oxygen species scavengers on fibrinolytic activity of some pro- Peng, F., D. Triplett, L. Barna. Direct PCR of leukocytes treated teinases. 82:303 with microwave irradiation to detect factor V Leiden muta- tion. 82:193 Qi, R., Y. Ozaki, K. Satoh, K. Kurota, N. Asazuma, Y. Yatomi, Peng, F., D. Triplett, L. Barna, D. Morrical. Pulmonary embolism S. Kume. Quantitative measurement of various 5-HT receptor and premature labor in a patient with both factor V Leiden mutation and methylenetetrahydrofolate reductase gene C677T antagonists on platelet activation induced by serotonin. 81:43 mutation. 83:243 Qi, R., see Satoh, K. 81:515 Peng, F., see Hoagland, L.E. 83:363 Pereira, J., see Aranda, E. 84:67 Racanelli, A., see Wong, P.C. 83:117 Perrone, M.H., see Bostwick, J.S. 82:495 Rahr, H.B., D. Danielsen, B.S. Andersen, L.C. Borris, M.R. Las- Pescador, R., see Fisher, J. 81:55 sen. Poor correlation between soluble fibrin concentrations Peskar, B.A., see Schmid, P. 81:451 measured by two commercially available immunoassays. 81:607 , see Sinzinger, H. 84:475 Raife, T.J., see Newell, A.A. 84:373 Peternel, P., see Grubic, N. 84:431 Rampin, E., see Cella, G. 81:671 Pettirossi, G., see Basili, S. 84:279 Raneli, G., see Avellone, G. 81:277 Pfaffenbach, G.M., J.A. Bussel, P. Rubinstein. A rapid genotype Rao, G.H.R., see White, J.G. 84:253 assay for PI* haplotypes. 81:353 Rao, L.V.M., see Zivelin, A. 82:429 Phillips, D.J., M.S. Novinger, B.L. Evatt, W.C. Hooper. TNF-a Rapaport, S.I., see Zivelin, A. 82:429 suppresses IL-la and IL-6 upregulation of C4b-binding protein Rascle, F., see Tardy, B. 83:153 in HepG-2 hepatoma cells. 81:307 Raut, S., P.J. Gaffney. Interaction of heparin with fibrinogen using Phillips, D.J., see Benson, J.M. 83:87 surface plasmon resonance technology: investigation of heparin , see Hooper, W.C. 81:315 binding site on fibrinogen. 81:503 Pich, I., C. de Castellarnau. Plasma stimulation of prostacyclin Raut, S., see Boutcher, P.A. 81:231 production by rat smooth muscle cells requires previous induc- Rawlins, P., see Hooper, W.C. 81:577 tion of phospholipase activity. 82:323 Razavian, S.M., see Keddad, K. 82:159 Pidlich, J., see Ulm, M.R. 83:237 Pietrucha, T., see Golanski, J. 83:199 Reed, S.V., see Denson, K.W.E. 81:151 Pignaud, G., see Bal dit Sollier, C. 81:427 Reininger, A., see Gawaz, M. 83:341 , see Roussi, J. 81:297 Reininger, A.J., see Reininger, C.B. 82:523 Pinot, A., see Gralnick, H.R. 81:113 Reininger, C.B., J. Graf, A.J. Reininger, M. Spannagl, B. Steck- Piretto, V., see Anfossi, G. 82:57 meier, L. Schweiberer. Increased platelet and coagulatory activ- Pirich, C., Y. Efthimiou, J. O’Grady, C. Zielinski, H. Sinzinger. ity indicate ongoing thrombogenesis in peripheral arterial dis- Apolipoprotein A and biological half-life of prostaglandin I, in ease. 82:523 HIV-1 infection. 81:213 Reininger, C.B., A. Greinacher, J. Graf, R. Lasser, B. Steckmeier, Author Index/Thrombosis Research 88 (1997) 509-520 L. Schweiberer. Platelets of patients with peripheral arterial epinephrine-induced activation: a study using the particle count- disease are hypersensitive to heparin. 81:641 ing method based upon light scattering. 81:515 Reininger, I.M., see Burke, S.E. 83:421 Satoh, K., see Qi, R. 81:43 Reiter, M., see Fischer, B.E. 84:55 Sawamoto, Y., M. Shima, M. Yamamoto, S. Kamisue, H. Nakai, Ribeiro, M.J.A., see Hooper, W.C. 81:577 I. Tanaka, K. Hayashi, J.C. Giddings, A. Yoshioka. Measure- Risgen, U.C., see Rgnning, H.F. 84:73 ment of anti-factor [IX IgG subclasses in haemophilia B patients Rivers, R.P.A., see Stephens, A.C. 81:545 who developed inhibitors with episodes of allergic reactions to Rgnning, H.F., U.C. Risgen, L. Orning, K. Sletten, K.S. Sakarias- factor 1X concentrates. 83:279 sen. Synthetic peptide analogs of tissue factor and factor VII Sayinalp, N., see Ozdemir, O. 84:121 which inhibit factor Xa formation by the tissue factor/factor Sbarai, A., see Cella, G. $1:671 Vila complex. 84:73 Scharrer, I., see Galanakis, D. 81:263 Rosén, U., see Zdller, B. 83:475 Schlit, A.-F., C. Col-De Beys, M. Moriau, E. Lavenne-Pardonge. Rosengart, A., see Kessler, C. 84:145 Acquired activated protein C resistance in pregnancy. 84:203 Rossing, P., see Myrup, B. 81:485 Schmid, P., G. Karanikas, H. Kritz, C. Pirich, Y. Stamatopoulos, Rota, S., P.D. Flynn, N.J. Wareham, T.P. Baglin, C.D. Byrne. Is B.A. Peskar, H. Sinzinger. Passive smoking and platelet throm- platelet phospholipid-dependent thrombin generation altered boxane. 81:45] by acute myocardial infarction or aspirin?. 83:329 Schneppenheim, R., see Nowak-Gottl, U. 81:665 Rotolo, G., see Avellone, G. 81:277 Schumacher, W.A., C.L. Heran, T.E. Steinbacher. Sensitivity of Roussi, J., P. André, M. Samama, G. Pignaud, M. Bonneau, A. experimental venous and arterial thrombosis and bleeding to Laporte, L. Drouet. Platelet functions and haemostasis parame- ancrod-induced defibrinogenation. 81:187 ters in pigs: absence of side effects of a procedure of general Schweiberer, L., see Reininger, C.B. 81:641, 82:523 anaesthesia. 81:297 Seghatchian, J., see Bessos, H. 84:367 Royo, T., see Pueyo, C. 81:101 , see Krailadsiri, P. 83:469 Ruan, C., see Xia, L. 81:477 Seki, J., see Aoki, T. 81:439 Rubinstein, P., see Pfaffenbach, G.M. 81:353 Selley, M.L., J.A. McGuiness, N.G. Ardlie. The effect of choles- Ruef, P., see Péschl, J.M.B. 81:283 terol oxidation products on human platelet aggregation. 83:449 Rydzewski, A., T. Urano, T. Hachiya, H. Kaneko, S. Baba, Y. Senzaki, K., see Aoki, T. 81:439 Takada, A. Takada. The effect of a SHT, receptor antagonist Septilveda, S., see Aranda, E. 84:67 sarpogrelate (MCI-9042) treatment on platelet function in Sheffield, W.P., see Syed, S. 84:419 Buerger’s disease. 84:445 Sheikhzadeh, A., see Kessler, C. 84:145 Shi, G.-Y., S.-J. Wang, B.-I. Chang, C.-F. Tasi, M.T. Lin, W.-C. Chang, L.-Y.C. Wing, C.J. Jen, H.-L. Wu. Regulation of Sabatino, R.D., see Bostwick, J.S. 82:495 plasminogen activator inhibitor activity by plasmin in endothe- Sahud, M., see Drasin, T. 84:179 lial cells. 81:75 Saito, H., see Yamazaki, T. 82:275 Shibuya, T., see Ikeda, M. 82:87 Saito, S., see Kanazuka, M. 82:51 Shigekiyo, T., see Kanazuka, M. 82:51 Sakariassen, K.S., see Rgnning, H.F. 84:73 Shima, M., see Sawamoto, Y. 83:279 , see Stephens, R.W. 84:453 Shimizu, A., see Iguchi, K. 84:137 Sakata, T., Y. Goto, K. Kario, Y. Katayama, T. Matsuyama, H. Shinoki, N., see Ikeda, M. 82:87 Kato, T. Miyata. Recurrent restenosis after percutaneous trans- luminal coronary angioplasty in a patient with congenital pro- , see Kambayashi, J.-i. 81:85 tein C deficiency and high activated factor VII level. 81:687 Shinya, H., N. Matsuo, N. Takeyama, T. Tanaka. Hyperammo- Sakata, T., K. Kario, Y. Katayama, T. Matsuyama, H. Kato, T. nemia inhibits platelet aggregation in rats. 81:195 Miyata. Clinical significance of activated protein C resistance Siegbahn, A., see Ernofsson, M. 83:307 as a potential marker for hypercoagulable state. 82:235 Sigurdardottir, O., see Valen, G. 83:321 Sakon, M., see Kambayashi, J.-i. 81:85 Silva, V., see Hooper, W.C. 81:577 Sakuragawa, N., see Iguchi, K. 84:137 Silverstein, R.L., see Simantov, R. 84:361 , see Ozawa, T. 81:595 Simantov, R., S.K. Lo, J.E. Salmon, L.R. Sammaritano, R.L. Sil- Salmon, D.M. Optimisation of platelet aggregometry utilising mi- verstein. Factor V Leiden increases the risk of thrombosis in crotitreplate technology and integrated software. 84:213 patients with antiphospholipid antibodies. 84:361 Salmon, J.E., see Simantov, R. 84:361 Simon, A., see Keddad, K. 82:159 Salte, R., K. Norberg, O.R. @degaard. Evidence of a protein Sinzinger, H., C. Pirich, J. Bednar, J. O’Grady. Ex-vivo and in-vivo C-like anticoagulant system in bony fish. 83:389. Correction. platelet function in patients with severe hypercholesterolemia 84:300 undergoing LDL-apheresis. 82:291 Samama, M., see Roussi, J. 81:297 Sinzinger, H., M.R. Ulm, I. Neumann, H. Kritz, J. O’Grady, B.A. Samama, M.M., see Gerotziafas, G.T. 81:491 Peskar. The prostacyclin stimulating plasma factor activity im- , see Tardy, B. 83:153 proves thromboresistance only if vascular PGI,-production is Sammaritano, L.R., see Simantov, R. 84:361 intact. 84:475 Samurkasoglu, B., see USurman, F. 84:295 Sinzinger, H., see Pirich, C. 81:213 Sanchez de la Cuesta, F., see De La Cruz, J.P. 81:327 , see Schmid, P. 81:451 , see Gonzalez-Correa, J.A. 81:367 , see Ulm, M.R. 83:237 Sandset, P.M., see Iversen, N. 84:267 Sipit, T., see Ugurman, F. 84:295 , see Jacobsen, E.M. 83:339 Skjgnsberg, O.H., see Bach-Gansmo, E.T. 82:177 Santoro, N., see Bottasso, B. 81:345 Skrzypek, E., S.C. Straley. Interaction between Yersinia pestis Satoh, K., Y. Ozaki, R. Qi, L. Yang, N. Asazuma, Y. Yatomi, S. YopM protein and human a-thrombin. 84:33 Kume. Factors that affect the size of platelet aggregates in Sletten, K., see Rénning, H.F. 84:73